Development and validation of an LC-MS-based quantification assay for new therapeutic antibodies: application to a novel therapy against herpes simplex virus

Multiple therapeutic monoclonal antibodies (mAbs) are currently under development or in (pre)clinical study phases to reach regulatory approval. Among these, a new mAb against herpes simplex virus, HDIT101, was recently tested in healthy volunteers during a phase I clinical trial (first-in-human, do...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fresnais, Margaux (VerfasserIn) , Longuespée, Rémi (VerfasserIn) , Sauter, Max (VerfasserIn) , Schaller, Torsten (VerfasserIn) , Arndt, Michaela (VerfasserIn) , Krauß, Jürgen (VerfasserIn) , Blank, Antje (VerfasserIn) , Haefeli, Walter E. (VerfasserIn) , Burhenne, Jürgen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 16, 2020
In: ACS omega
Year: 2020, Jahrgang: 5, Heft: 38, Pages: 24329-24339
ISSN:2470-1343
DOI:10.1021/acsomega.0c02547
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1021/acsomega.0c02547
Volltext
Verfasserangaben:Margaux Fresnais, Rémi Longuespée, Max Sauter, Torsten Schaller, Michaela Arndt, Jürgen Krauss, Antje Blank, Walter E. Haefeli, and Jürgen Burhenne

MARC

LEADER 00000caa a2200000 c 4500
001 1738019691
003 DE-627
005 20230426130456.0
007 cr uuu---uuuuu
008 201105s2020 xx |||||o 00| ||eng c
024 7 |a 10.1021/acsomega.0c02547  |2 doi 
035 |a (DE-627)1738019691 
035 |a (DE-599)KXP1738019691 
035 |a (OCoLC)1341375917 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fresnais, Margaux  |e VerfasserIn  |0 (DE-588)1190043157  |0 (DE-627)1668720108  |4 aut 
245 1 0 |a Development and validation of an LC-MS-based quantification assay for new therapeutic antibodies  |b application to a novel therapy against herpes simplex virus  |c Margaux Fresnais, Rémi Longuespée, Max Sauter, Torsten Schaller, Michaela Arndt, Jürgen Krauss, Antje Blank, Walter E. Haefeli, and Jürgen Burhenne 
264 1 |c September 16, 2020 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.11.2020 
520 |a Multiple therapeutic monoclonal antibodies (mAbs) are currently under development or in (pre)clinical study phases to reach regulatory approval. Among these, a new mAb against herpes simplex virus, HDIT101, was recently tested in healthy volunteers during a phase I clinical trial (first-in-human, dose escalation). In the frame of the pharmacokinetic evaluation of this new therapy, a mass spectrometric (MS)-based method was developed for the quantification of HDIT101 in human plasma using liquid chromatography coupled to tandem mass spectrometry. In this work, we describe the development of this bioanalytical assay using the quantification of a HDIT101 surrogate peptide, the assay validation procedure according to the FDA guidelines within the calibration range from 20 to 5000 μg/mL, and its application to plasma samples from the first-in-human clinical trial. This work presents a generic workflow for the development of MS-based quantification assays of new therapeutic antibodies that allows reaching high immunopurification recovery (>98% for HDIT101 over the full calibration range with a precision of 6.9% CV). Surrogate peptide and stable isotopically labeled internal standard were stable, and batch-to-batch accuracies and precisions at the four quality standard levels ranged between −2 and 5% bias and 8 and 11% CV, respectively. 
700 1 |a Longuespée, Rémi  |e VerfasserIn  |0 (DE-588)113707146X  |0 (DE-627)89404690X  |0 (DE-576)491093179  |4 aut 
700 1 |a Sauter, Max  |e VerfasserIn  |0 (DE-588)1103516507  |0 (DE-627)86126813X  |0 (DE-576)470642033  |4 aut 
700 1 |a Schaller, Torsten  |e VerfasserIn  |0 (DE-588)1155841174  |0 (DE-627)1018325425  |0 (DE-576)501895574  |4 aut 
700 1 |a Arndt, Michaela  |e VerfasserIn  |0 (DE-588)1084612712  |0 (DE-627)848572076  |0 (DE-576)456369635  |4 aut 
700 1 |a Krauß, Jürgen  |d 1960-  |e VerfasserIn  |0 (DE-588)120665301  |0 (DE-627)70490778X  |0 (DE-576)292329083  |4 aut 
700 1 |a Blank, Antje  |e VerfasserIn  |0 (DE-588)1061215962  |0 (DE-627)805162364  |0 (DE-576)174275722  |4 aut 
700 1 |a Haefeli, Walter E.  |d 1958-  |e VerfasserIn  |0 (DE-588)124572359  |0 (DE-627)656806141  |0 (DE-576)340514221  |4 aut 
700 1 |a Burhenne, Jürgen  |d 1963-  |e VerfasserIn  |0 (DE-588)1034228889  |0 (DE-627)745126987  |0 (DE-576)381858197  |4 aut 
773 0 8 |i Enthalten in  |t ACS omega  |d Washington, DC : ACS Publications, 2016  |g 5(2020), 38, Seite 24329-24339  |h Online-Ressource  |w (DE-627)863132308  |w (DE-600)2861993-6  |w (DE-576)474097676  |x 2470-1343  |7 nnas  |a Development and validation of an LC-MS-based quantification assay for new therapeutic antibodies application to a novel therapy against herpes simplex virus 
773 1 8 |g volume:5  |g year:2020  |g number:38  |g pages:24329-24339  |g extent:11  |a Development and validation of an LC-MS-based quantification assay for new therapeutic antibodies application to a novel therapy against herpes simplex virus 
856 4 0 |u https://doi.org/10.1021/acsomega.0c02547  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20201105 
993 |a Article 
994 |a 2020 
998 |g 1034228889  |a Burhenne, Jürgen  |m 1034228889:Burhenne, Jürgen  |d 910000  |d 910100  |e 910000PB1034228889  |e 910100PB1034228889  |k 0/910000/  |k 1/910000/910100/  |p 9  |y j 
998 |g 124572359  |a Haefeli, Walter E.  |m 124572359:Haefeli, Walter E.  |d 910000  |d 910100  |e 910000PH124572359  |e 910100PH124572359  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 1061215962  |a Blank, Antje  |m 1061215962:Blank, Antje  |d 910000  |d 910100  |e 910000PB1061215962  |e 910100PB1061215962  |k 0/910000/  |k 1/910000/910100/  |p 7 
998 |g 120665301  |a Krauß, Jürgen  |m 120665301:Krauß, Jürgen  |d 910000  |d 910100  |e 910000PK120665301  |e 910100PK120665301  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 1103516507  |a Sauter, Max  |m 1103516507:Sauter, Max  |d 910000  |d 910100  |e 910000PS1103516507  |e 910100PS1103516507  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 113707146X  |a Longuespée, Rémi  |m 113707146X:Longuespée, Rémi  |d 910000  |d 910100  |e 910000PL113707146X  |e 910100PL113707146X  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1190043157  |a Fresnais, Margaux  |m 1190043157:Fresnais, Margaux  |d 50000  |e 50000PF1190043157  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1738019691  |e 3792774038 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1738019691","note":["Gesehen am 05.11.2020"],"language":["eng"],"person":[{"display":"Fresnais, Margaux","given":"Margaux","roleDisplay":"VerfasserIn","role":"aut","family":"Fresnais"},{"family":"Longuespée","display":"Longuespée, Rémi","given":"Rémi","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Sauter","display":"Sauter, Max","role":"aut","roleDisplay":"VerfasserIn","given":"Max"},{"family":"Schaller","given":"Torsten","roleDisplay":"VerfasserIn","role":"aut","display":"Schaller, Torsten"},{"family":"Arndt","given":"Michaela","roleDisplay":"VerfasserIn","role":"aut","display":"Arndt, Michaela"},{"family":"Krauß","display":"Krauß, Jürgen","given":"Jürgen","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Blank, Antje","given":"Antje","roleDisplay":"VerfasserIn","role":"aut","family":"Blank"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Walter E.","display":"Haefeli, Walter E.","family":"Haefeli"},{"display":"Burhenne, Jürgen","role":"aut","roleDisplay":"VerfasserIn","given":"Jürgen","family":"Burhenne"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["American Chemical Society"]},"origin":[{"publisherPlace":"Washington, DC","dateIssuedDisp":"[2016]-","publisher":"ACS Publications"}],"language":["eng"],"disp":"Development and validation of an LC-MS-based quantification assay for new therapeutic antibodies application to a novel therapy against herpes simplex virusACS omega","title":[{"title":"ACS omega","title_sort":"ACS omega"}],"id":{"eki":["863132308"],"zdb":["2861993-6"],"issn":["2470-1343"]},"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Chemical Society"}],"pubHistory":["Volume 1, issue 1 (July 2016)-"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"863132308","part":{"issue":"38","volume":"5","pages":"24329-24339","extent":"11","year":"2020","text":"5(2020), 38, Seite 24329-24339"},"note":["Gesehen am 25.06.2025"]}],"origin":[{"dateIssuedDisp":"September 16, 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Margaux Fresnais, Rémi Longuespée, Max Sauter, Torsten Schaller, Michaela Arndt, Jürgen Krauss, Antje Blank, Walter E. Haefeli, and Jürgen Burhenne"]},"id":{"doi":["10.1021/acsomega.0c02547"],"eki":["1738019691"]},"physDesc":[{"extent":"11 S."}],"title":[{"title_sort":"Development and validation of an LC-MS-based quantification assay for new therapeutic antibodies","title":"Development and validation of an LC-MS-based quantification assay for new therapeutic antibodies","subtitle":"application to a novel therapy against herpes simplex virus"}]} 
SRT |a FRESNAISMADEVELOPMEN1620